Approaches based on cholinergic hypothesis and cholinesterase inhibitors in the treatment of Alzheimer's disease

Basit Öğe Kaydı
dc.authorscopusid57213636835
dc.authorscopusid35082483800
dc.authorscopusid7006287371
dc.contributor.authorÖzdemir Z.
dc.contributor.authorÖzçelik A.-B.
dc.contributor.authorUysal M.
dc.date.accessioned2024-08-04T20:03:41Z
dc.date.available2024-08-04T20:03:41Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAlzheimer’s disease (AD) is a progressive and fatal neurodegenerative disease which deteriorates a person's ability to perform daily activities, leading to various neuropsychiatric symptoms and behavioral disorders in later stages of the disease. The pathophysiology of AD is complex. Biochemical studies indicate that some neuromediator levels, especially acetylcholine, are reduced in the brain cortex. Loss of neurons and axons associated with the onset of the disease causes lower levels of acetylcholine release and it is more difficult to maintain the continuity of nerve conduction in low concentration neurotransmitter levels. This has led to the introduction of a “cholinergic hypothesis” that emphasizes the importance of acetylcholine deficiency in the development of the symptoms of the disease. As the (AChE) and (BChE) enzymes from the serine hydrolases which perform the hydrolysis process of acetylcholine (ACh), the inhibition of these enzymes is an important method of raising the level of acetylcholine. Studies indicate that increases in acetylcholine levels due to acetylcholine esterase inhibition may improve cognitive impairment in the early stages of AD. © 2019 Bentham Science Publishers.en_US
dc.identifier.doi10.2174/9789811401893119080007
dc.identifier.endpage190en_US
dc.identifier.issn2451-8743
dc.identifier.scopus2-s2.0-85071032073en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage154en_US
dc.identifier.urihttps://doi.org/10.2174/9789811401893119080007
dc.identifier.urihttps://hdl.handle.net/11616/92019
dc.identifier.volume8en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBentham Science Publishersen_US
dc.relation.ispartofFrontiers in Clinical Drug Research - Alzheimer Disordersen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcetylcholineen_US
dc.subjectAChE Inhibitorsen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectBChE Inhibitorsen_US
dc.subjectCholinergic hypothesisen_US
dc.subjectDonepezileen_US
dc.subjectGalantamineen_US
dc.subjectHuperzin Aen_US
dc.subjectMetrifonateen_US
dc.subjectPhysostigmineen_US
dc.subjectRivastigmineen_US
dc.subjectTacrineen_US
dc.titleApproaches based on cholinergic hypothesis and cholinesterase inhibitors in the treatment of Alzheimer's diseaseen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu